ASND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ascendis Pharma A/S (ASND) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. Despite recent price declines, the company's strong growth potential, bullish analyst ratings, and positive long-term catalysts make it a compelling investment opportunity.
The stock's MACD is negative and expanding downward, indicating bearish momentum. However, the RSI is at 27.43, suggesting the stock is nearing oversold territory. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its S1 support level of 228.545, which could act as a floor for the price.
Analysts have consistently raised price targets, with the latest targets ranging from $256 to $332, citing strong growth potential from Yorvipath and Yuviwel.
The company recently announced the redemption of $575 million in convertible senior notes, reflecting strong stock performance.
The accelerated approval of Yuviwel and its potential to disrupt the achondroplasia market are significant growth drivers.
Hedge funds are selling, with a 565.41% increase in selling activity over the last quarter.
Financial performance shows a drop in net income (-12.76% YoY) and EPS (-14.06% YoY), which may concern some investors.
The MACD indicates bearish momentum, and the stock has a 50% chance of a 0% change in the next day and a -2.57% decline in the next week.
In Q4 2025, revenue increased by 42.31% YoY to $247.5 million, showcasing strong top-line growth. However, net income dropped by -12.76% YoY to -$33.56 million, and EPS declined by -14.06% YoY to -0.55. Gross margin remains high at 90.47%, though it decreased slightly by -1.60% YoY.
Analysts are overwhelmingly bullish on ASND, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The average price target is significantly higher than the current price, reflecting strong confidence in the company's growth trajectory.
